MEREO BIOPHARMA GROUP PLC Increase Through New Leases Liabilities Arising From Financing Activities
MEREO BIOPHARMA GROUP PLC (MREO) reported Increase Through New Leases Liabilities Arising From Financing Activities of GBP 910.00 thousand for the 12-month period ending 2021-12-31, per its 20-F filed 2023-03-28.
Discontinued › Cash Flow › Financing Activities
ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities · last filed 2023-03-28
| Period end | Increase Through New Leases Liabilities Arising From Financing Activities 12 month |
|---|---|
| 2021-12-31 | 910.00K GBP 20-F · filed 2023-03-28 |
| 2019-12-31 | 2.53M GBP 20-F · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |